Schwarer, Anthony

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

Fajgenbaum, D. C., Langan, R.-A., Japp, A. S., Partridge, H. L., Pierson, S. K., Singh, A., Arenas, D. J., Ruth, J. R., Nabel, C. S., Stone, K., et al. (2019) · Journal of Clinical Investigation

IgG4-Related and Inflammatory DiseasesViral-associated cancers and disorders

Cited by 147

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Fox, L. C., Cummins, K. D., Costello, B., Yeung, D., Cleary, R., Forsyth, C., Tatarczuch, M., Burbury, K., Motorna, O., Shortt, J., et al. (2017) · Blood Advances

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 43